Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Ophthalmology

The Journey of Your Vision: Symptoms and Progression

At a Glance

Central Areolar Choroidal Dystrophy (CACD) is a slow-progressing genetic eye condition that gradually causes central vision loss over 10 to 20 years. While it can cause legal blindness, it almost always preserves your peripheral vision, meaning you do not experience total black blindness.

Central Areolar Choroidal Dystrophy (CACD) is a progressive condition, but its journey is often measured in decades rather than days. Because it is a “slow-motion” condition, many patients find they have ample time to adapt to changes as they occur. While progression varies from person to person, it typically takes 10 to 20 years from the onset of the first subtle symptoms to reach the late stage of significant central vision loss. Understanding the specific ways your vision might change can help you prepare for the future without unnecessary fear.

Early Symptoms: The First Signs

For many people, the first signs of CACD appear in adulthood, often between the ages of 30 and 50 [1][2]. In the earliest stages, you might not notice any change in your vision at all, even if a doctor can see subtle changes in your retina using specialized imaging [3][4].

As the condition begins to affect the macula (the center of the retina), you may experience:

  • Mild Blurring: You might feel like your glasses prescription is slightly “off,” particularly when trying to read fine print or see small details [1].
  • Metamorphopsia (met-ah-more-FOP-see-ah): This is a medical term for distorted vision [1]. You may notice that straight lines—like the edge of a door or lines on a page—appear wavy, bent, or irregular.
  • Subtle Color Changes: Colors may seem slightly less vibrant or harder to distinguish in the center of your vision.

Mid-Stage: Noticeable Changes

As CACD progresses, the thinning of the retinal layers (the RPE and choriocapillaris) becomes more pronounced [5][3]. During this phase, you may notice:

  • Decreased Visual Acuity: Your “sharp” vision continues to decline, making tasks like driving or reading standard text increasingly difficult [6][7].
  • Central Scotoma: You may begin to notice a “blind spot” or a gray/blurred area directly in the center of your vision [8][5]. This makes it hard to see what you are looking at directly, though you can still see things around the edges of that spot.
  • Contrast Sensitivity Issues: It may become harder to see objects against a similarly colored background, such as a white plate on a white tablecloth [9][10].

The Realities of Driving and Vocation

Since CACD frequently appears during your peak working years, the practical impacts on your life are a major concern. As your central vision declines, you will need to evaluate your ability to drive safely. Proactively discuss your visual fields and local DMV legal requirements with your low-vision specialist. It is much better to plan for this transition than to wait for an accident. Additionally, vocational rehabilitation services can provide workplace accommodations, specialized training, and tools to help you maintain your career and independence as your vision changes.

Late-Stage: Living with Central Loss

In the later stages of CACD, the central atrophy (thinning) usually becomes “well-demarcated,” meaning it has a clear boundary [5][6].

  • Significant Central Loss: While central vision may become very limited, many patients experience foveal sparing, where a tiny island of clear vision remains in the very center for many years [11].
  • Preserved Side Vision: Importantly, your peripheral (side) vision almost always remains intact [5][11]. You will likely still be able to see shapes, movement, and light around the room, which helps you stay mobile and navigate your environment independently.
  • Defining “Blindness”: While you may meet the criteria for “legal blindness” due to the loss of central acuity (typically 20/200 or worse), this is very different from “total blindness” (seeing only black) [12][13]. Most people with CACD continue to see the world around their central blind spot.

How CACD Differs from Other Conditions

It is common for CACD to be mistaken for other eye problems, particularly Age-Related Macular Degeneration (AMD), because both affect the macula [5][14]. However, there are key differences:

  • Age of Onset: CACD often starts much earlier (in your 30s or 40s), whereas AMD typically affects people over 60 [1][5].
  • Genetics: CACD is caused by specific gene mutations (like PRPH2) and follows a clear family inheritance pattern [15][8].
  • Appearance: Doctors looking at the retina will see that CACD lacks the “drusen” (yellow waste deposits) typically found in the early stages of AMD [6][3].

Understanding these differences is why genetic testing is often recommended to confirm a CACD diagnosis and provide a clearer picture of your specific timeline [14][16].

Return to Home Page

Common questions in this guide

How long does it take for CACD to progress?
CACD is a slow-progressing condition. It typically takes 10 to 20 years from the onset of the very first subtle symptoms to reach the late stage of significant central vision loss.
Will Central Areolar Choroidal Dystrophy make me completely blind?
No, CACD almost always preserves your peripheral (side) vision. While you may experience significant central vision loss and meet the criteria for legal blindness, you will generally still be able to see shapes, movement, and light around you.
How is CACD different from age-related macular degeneration (AMD)?
CACD usually begins earlier than AMD, often in your 30s or 40s, and is caused by specific inherited gene mutations. Additionally, doctors examining your retina will not see the yellow waste deposits, called drusen, that are typically found in AMD.
What are the first signs of CACD?
Early symptoms often appear between ages 30 and 50. These can include mild blurring, straight lines appearing wavy or bent, and colors seeming slightly less vibrant in the center of your vision.
What does foveal sparing mean?
Foveal sparing occurs when a tiny island of clear, sharp vision remains in the very center of your eye, even as the surrounding central vision begins to decline in the later stages of the condition.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I currently showing signs of 'foveal sparing,' and how might that affect my vision over the next few years?
  2. 2.How does my specific genetic mutation (e.g., PRPH2) typically influence the speed of disease progression?
  3. 3.Are the changes you see in my retina more consistent with CACD or age-related macular degeneration (AMD)?
  4. 4.What specific imaging tests (like OCTA or autofluorescence) will you use to monitor the thinning of my choriocapillaris?
  5. 5.At what point should we begin discussing low-vision aids or vocational rehabilitation if my central vision continues to decline?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    LONG-TERM FOLLOW-UP OF PRPH2 -ASSOCIATED RETINAL DYSTROPHY.

    Zhao Z, Miere A, Le HM, Souied EH

    Retinal cases & brief reports 2024; (18(2)):236-241 doi:10.1097/ICB.0000000000001351.

    PMID: 36053859
  2. 2

    Retinal Dystrophies Associated With Peripherin-2: Genetic Spectrum and Novel Clinical Observations in 241 Patients.

    Heath Jeffery RC, Thompson JA, Lo J, et al.

    Investigative ophthalmology & visual science 2024; (65(5)):22 doi:10.1167/iovs.65.5.22.

    PMID: 38743414
  3. 3

    MULTIMODAL RETINAL IMAGING REVEALS NEW PATHOGENIC INSIGHTS IN CENTRAL AREOLAR CHOROIDAL DYSTROPHY: A CASE SERIES.

    Romano F, Cozzi E, Boon CJF, et al.

    Retinal cases & brief reports 2024; (18(1)):32-38 doi:10.1097/ICB.0000000000001325.

    PMID: 36731070
  4. 4

    Structure-function correlation of retinal photoreceptors in PRPH2-associated central areolar choroidal dystrophy patients assessed by high-resolution scanning laser imaging and microperimetry.

    Mulders T, van der Zanden L, Klevering BJ, et al.

    Acta ophthalmologica 2024; (102(5)):521-528 doi:10.1111/aos.15816.

    PMID: 38041245
  5. 5

    New Insights on the Regulatory Gene Network Disturbed in Central Areolar Choroidal Dystrophy-Beyond Classical Gene Candidates.

    Kazmierczak de Camargo JP, Prezia GNB, Shiokawa N, et al.

    Frontiers in genetics 2022; (13()):886461 doi:10.3389/fgene.2022.886461.

    PMID: 35656327
  6. 6

    PRPH2-Associated Macular Dystrophy in 4 Family Members with a Novel Mutation.

    Choi H, Cloutier A, Lally D

    Ophthalmic genetics 2022; (43(2)):235-239 doi:10.1080/13816810.2021.2015790.

    PMID: 34906036
  7. 7

    Phenotypic Differences in a PRPH2 Mutation in Members of the Same Family Assessed with OCT and OCTA.

    Albertos-Arranz H, Sánchez-Sáez X, Martínez-Gil N, et al.

    Diagnostics (Basel, Switzerland) 2021; (11(5)) doi:10.3390/diagnostics11050777.

    PMID: 33925984
  8. 8

    A Specific Macula-Predominant Retinal Phenotype Is Associated With the CDHR1 Variant c.783G>A, a Silent Mutation Leading to In-Frame Exon Skipping.

    Charbel Issa P, Gliem M, Yusuf IH, et al.

    Investigative ophthalmology & visual science 2019; (60(10)):3388-3397 doi:10.1167/iovs.18-26415.

    PMID: 31387115
  9. 9

    Importance of Screening for Contrast Sensitivity, Falls, and Mobility Limitations in Older Adults With Maculopathy.

    Agathos CP, Shanidze NM, Fletcher DC

    American journal of ophthalmology 2025; (280()):481-492 doi:10.1016/j.ajo.2025.08.051.

    PMID: 40889625
  10. 10

    Measuring the Contrast Sensitivity Function in Non-Neovascular and Neovascular Age-Related Macular Degeneration: The Quantitative Contrast Sensitivity Function Test.

    Vingopoulos F, Wai KM, Katz R, et al.

    Journal of clinical medicine 2021; (10(13)) doi:10.3390/jcm10132768.

    PMID: 34202569
  11. 11

    Foveal Sparing in Central Retinal Dystrophies.

    Bax NM, Valkenburg D, Lambertus S, et al.

    Investigative ophthalmology & visual science 2019; (60(10)):3456-3467 doi:10.1167/iovs.18-26533.

    PMID: 31398255
  12. 12

    Glaucoma Blindness at a Tertiary Eye Care Center.

    Stone JS, Muir KW, Stinnett SS, Rosdahl JA

    North Carolina medical journal 2015; (76(4)):211-8 doi:10.18043/ncm.76.4.211.

    PMID: 26509509
  13. 13

    Prevalence of vision loss among hospital in-patients; a risk factor for falls?

    Leat SJ, Zecevic AA, Keeling A, et al.

    Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) 2018; (38(1)):106-114 doi:10.1111/opo.12428.

    PMID: 29265472
  14. 14

    Genetic screening for macular dystrophies in patients clinically diagnosed with dry age-related macular degeneration.

    Kersten E, Geerlings MJ, Pauper M, et al.

    Clinical genetics 2018; (94(6)):569-574 doi:10.1111/cge.13447.

    PMID: 30215852
  15. 15

    Prph2 knock-in mice recapitulate human central areolar choroidal dystrophy retinal degeneration and exhibit aberrant synaptic remodeling and microglial activation.

    Ruiz-Pastor MJ, Sánchez-Sáez X, Kutsyr O, et al.

    Cell death & disease 2023; (14(11)):711 doi:10.1038/s41419-023-06243-8.

    PMID: 37914688
  16. 16

    Clinical and Imaging Characteristics of PRPH2 Retinopathies in a Longitudinal Cohort and Diagnostic Implications.

    Seddon JM, De D, Grunenkovaite L, Ferrara D

    Investigative ophthalmology & visual science 2024; (65(14)):31 doi:10.1167/iovs.65.14.31.

    PMID: 39693084

This page provides educational information about the symptoms and progression of CACD. It does not replace professional medical advice. Always consult your ophthalmologist or low-vision specialist to monitor and manage your specific vision changes.

Get notified when new evidence is published on Central areolar choroidal dystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.